Skip to main content
Equibles
TLSI logo

TLSI

TriSalus Life Sciences, Inc.
$4.69 +0.23 (+5.16%) At close · Jul 2
Market Cap
$288.04M
Shares
61,416,535

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$4.69 Open$4.51 Day$4.39–4.70 52W$2.20–7.95 Avg vol 30d439K Short int2.2M · 3.6% float · 6.8d Short vol89% Last earningsMay 12, 2026 DataFeb 2021–Jul 2026 Filing10-Q · May 12
Equibles Rating blended score · not investment advice
Overall
Buy
Technical · trend & momentum Buy
◦ 50 / 200-day cross no cross
◦ Price vs 200-day avg −3% below
+ Price vs 50-day avg +21% above
◦ RSI (14) 64 · neutral
+ MACD trend positive
◦ 52-week position 43% · mid-range
Sentiment · smart money Bullish
◦ Trend (MA cross) 50d $4 › 200d $5 — 200d above 50d
+ Institutional flow +31% holders QoQ · +32 funds added
+ Insider flow Net +$1.8M over 90 days · 17% sells
− Short interest 3.56% of float · ▲ +4.1% MoM · 6.8 days cover
◦ Volume signal Volume near normal
+ Institution breadth 84 holders — near 3-yr high, broad support
Fundamentals Strong
+ Revenue growth +53% Y/Y
+ Gross margin 85%, contracting
− EPS growth −40% Y/Y
− Free cash flow $-18.9M
+ Balance sheet net cash $20.4M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next
Next earnings call
Aug 19, 2026 Est · unconfirmed · in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 12, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Guidance & track record
      Latest guidance · from the 8-K filed May 12, 2026
      Revenue · 2026 Initiated $54M – $57M
      prior FY $45.15M midpoint +22.9% Y/Y

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 2
      50 / 200-day cross
      no cross Neutral
      Price vs 200-day avg
      −3% below Neutral
      Price vs 50-day avg
      +21% above Bullish
      RSI (14)
      64 · neutral Neutral
      MACD trend
      positive Bullish
      52-week position
      43% · mid-range Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $4 › 200d $5 — 200d above 50d
      Institutional flow Accumulating
      +31% holders QoQ · +32 funds added
      Insider flow Accumulating
      Net +$1.8M over 90 days · 17% sells
      Short interest Rising
      3.56% of float · ▲ +4.1% MoM · 6.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      84 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $2 Now $5 · 43% 52-wk high $8
      vs 200-day avg -3% vs 50-day avg +21%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Adjusted EBITDA losses non-GAAP -$5.8M Q1 2026 —
      Adjusted EBITDA non-GAAP -$17.2M the year ended December 31, 2025 —
      Gross margin 84.6% the year ended December 31, 2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      TLSI
      TriSalus Life Sciences, Inc.
      this stock
      		$288.04M -32.8% +59.0% — 3.6%
      ABT
      Abbott Laboratories
      		 $166.17B -23.5% +5.7% 26.7 1.3%
      SYK
      Stryker Corp
      		 $125.18B -6.8% +11.2% 37.8 1.6%
      MDT
      Medtronic plc
      		 $106.49B -12.7% +8.4% 22.3 1.4%
      BSX
      Boston Scientific Corp
      		 $67.09B -52.7% +5.5% 18.9 2.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      84
      % held
      33.6%
      Net QoQ
      +9.2M sh
      Top holder
      First Light Asset Managem…
      Held Float
      View
      Held by Funds
      Fund positions
      80
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      2.2M
      Days to cover
      6.8d
      Change
      +87.2K sh
      View
      Short Volume
      Short vol %
      89%
      As of
      Jul 2, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      3.8K
      Value
      $13.9K
      As of
      Jun 12, 2026
      View
      Off-Exchange
      Off-exchange %
      45.6%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Cluster buy
      Net (90d)
      +$1.8M
      Buyers / Sellers
      5 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $45.2M
      Net income (FY)
      $-39.2M
      EPS diluted
      $-1.84
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      May 14, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $135.0K
      Shares
      30.0K
      Filed
      Dec 10, 2024
      View
      Exempt Offerings
      Offering
      $22.0M
      Filed
      May 8, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 12, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      TLSI +7.3% +47.5% -23.6% +3.1% -32.8%
      SPY +1.4% -1.3% +8.0% -0.3% +9.2%
      vs SPY +5.9% +48.7% -31.6% +3.4% -42.0%
      Key facts CIK 1826667 CUSIP 89680M101 Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)